Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with ezabenlimab in patients with advanced or metastatic solid tumors.
Details
Age
Adult
Locations
CTRC Inpatient
University of Colorado Hospital
Principal Investigator
Robert Lentz
Study ID
Protocol Number: 23-2048
More information available at ClinicalTrials.gov: NCT05155332
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers